MX342409B - Tratamiento de enfermedades cardiacas. - Google Patents
Tratamiento de enfermedades cardiacas.Info
- Publication number
- MX342409B MX342409B MX2012008440A MX2012008440A MX342409B MX 342409 B MX342409 B MX 342409B MX 2012008440 A MX2012008440 A MX 2012008440A MX 2012008440 A MX2012008440 A MX 2012008440A MX 342409 B MX342409 B MX 342409B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- cardiac conditions
- glucagon
- dobutamine
- norepinephrine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere al tratamiento de la disfunción cardíaca. En concreto, ciertos compuestos, que se cree que son compuestos agonistas dobles de glucagón GLP-1, ejercen un efecto inotrópico positivo al tiempo que se conserva el equilibrio energético del corazón y, por tanto, pueden ser superiores a los agentes inotrópicos conocidos tales como dobutamina, norepinefrina y glucagón.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29665710P | 2010-01-20 | 2010-01-20 | |
PCT/DK2011/050018 WO2011088837A1 (en) | 2010-01-20 | 2011-01-20 | Treatment of cardiac conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012008440A MX2012008440A (es) | 2012-08-15 |
MX342409B true MX342409B (es) | 2016-09-28 |
Family
ID=43928934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012008440A MX342409B (es) | 2010-01-20 | 2011-01-20 | Tratamiento de enfermedades cardiacas. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20130157953A1 (es) |
EP (1) | EP2525809B1 (es) |
JP (2) | JP2013517307A (es) |
KR (1) | KR20120128129A (es) |
CN (1) | CN102892425A (es) |
AU (1) | AU2011206979B2 (es) |
BR (1) | BR112012018104A2 (es) |
CA (1) | CA2786934A1 (es) |
CL (1) | CL2012002037A1 (es) |
EA (1) | EA026384B1 (es) |
IL (1) | IL220876A0 (es) |
MX (1) | MX342409B (es) |
NZ (1) | NZ601167A (es) |
WO (1) | WO2011088837A1 (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8685919B2 (en) | 2008-12-15 | 2014-04-01 | Zealand Pharma A/S | Glucagon analogues |
EA020497B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
EP2370462B1 (en) | 2008-12-15 | 2014-07-16 | Zealand Pharma A/S | Glucagon analogues |
CN102292347A (zh) | 2008-12-15 | 2011-12-21 | 西兰制药公司 | 胰高血糖素类似物 |
JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
JP5969461B2 (ja) | 2010-04-27 | 2016-08-17 | ジーランド ファーマ アクティーゼルスカブ | Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用 |
AR081975A1 (es) * | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
US9169310B2 (en) * | 2010-06-24 | 2015-10-27 | Zealand Pharma A/S | Glucagon analogues |
AU2012331053A1 (en) | 2011-11-03 | 2014-05-29 | Zealand Pharma A/S | GLP-1 receptor agonist peptide gastrin conjugates |
WO2013092703A2 (en) * | 2011-12-23 | 2013-06-27 | Zealand Pharma A/S | Glucagon analogues |
CN104470948B (zh) | 2012-05-03 | 2018-06-15 | 西兰制药公司 | Gip-glp-1双激动剂化合物及方法 |
CA2878991C (en) | 2012-07-23 | 2021-12-07 | Zealand Pharma A/S | Glucagon analogues |
TWI608013B (zh) * | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
CN117903257A (zh) * | 2012-11-20 | 2024-04-19 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抗性的改良的肽药物 |
JP2016503046A (ja) * | 2012-12-19 | 2016-02-01 | ノヴォ ノルディスク アー/エス | コレステロール流出活性を有する新規glp−1受容体アゴニスト |
CN104902919B (zh) | 2012-12-21 | 2018-11-20 | 赛诺菲 | Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂 |
RS59124B1 (sr) | 2013-04-18 | 2019-09-30 | Novo Nordisk As | Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu |
UA122767C2 (uk) * | 2013-10-17 | 2021-01-06 | Зіленд Фарма А/С | Ацильований аналог глюкагону |
US9988429B2 (en) * | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
TWI670281B (zh) | 2013-11-06 | 2019-09-01 | 西蘭製藥公司 | Gip-glp-1雙重促效劑化合物及方法 |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
CN103724424B (zh) * | 2013-12-27 | 2015-05-27 | 浙江省农业科学院 | 一种mPEG-SPA-pGLP-2复合物及其制备方法和应用 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
WO2015185640A1 (en) | 2014-06-04 | 2015-12-10 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
EP3204408B1 (en) * | 2014-10-10 | 2020-05-06 | Novo Nordisk A/S | Stable glp-1 based glp-1/glucagon receptor co-agonists |
WO2016066744A2 (en) | 2014-10-29 | 2016-05-06 | Zealand Pharma A/S | Gip agonist compounds and methods |
WO2016108586A1 (ko) * | 2014-12-30 | 2016-07-07 | 한미약품 주식회사 | 안정성이 증가된 글루카곤 유도체 |
KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
WO2016168388A2 (en) * | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
US10336802B2 (en) | 2015-04-16 | 2019-07-02 | Zealand Pharma A/S | Acylated glucagon analogue |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
UA127445C2 (uk) | 2015-06-30 | 2023-08-30 | Ханмі Фарм. Ко., Лтд. | Комбінація для лікування або профілактики метаболічного синдрому |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
CN115920077A (zh) | 2015-12-31 | 2023-04-07 | 韩美药品株式会社 | 胰高血糖素/glp-1/gip受体三重激动剂的长效缀合物 |
US11179444B2 (en) | 2016-06-09 | 2021-11-23 | Amidebio, Llc | Glucagon analogs and methods of use thereof |
PE20190355A1 (es) | 2016-06-29 | 2019-03-07 | Hanmi Pharm Ind Co Ltd | Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo |
RU2753193C2 (ru) | 2016-12-09 | 2021-08-12 | Зилэнд Фарма А/С | Ацилированные двойные агонисты glp-1/glp-2 |
CN116143939A (zh) * | 2017-11-24 | 2023-05-23 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多重活性蛋白 |
TWI809515B (zh) * | 2017-12-21 | 2023-07-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
WO2021083306A1 (zh) * | 2019-10-31 | 2021-05-06 | 东莞市东阳光生物药研发有限公司 | Glp-1/gcg双受体激动剂多肽 |
EP3842060A1 (en) * | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled lactam co-agonists of the glucagon and glp-1 receptors |
EP4148064A4 (en) * | 2020-05-09 | 2024-06-12 | Tianjin Institute Of Pharmaceutical Res Co Ltd | POLYPEPTIDE DERIVATIVE WITH AGONISTIC DOUBLE RECEPTOR ACTIVITY AND USE THEREOF |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69936446T2 (de) * | 1998-02-13 | 2008-03-06 | Amylin Pharmaceuticals, Inc., San Diego | Inotropische und diuretische effekte von exendin und glp-1 |
US6703359B1 (en) * | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
WO1999046283A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
MXPA02006118A (es) * | 2000-10-20 | 2004-08-23 | Amylin Pharmaceuticals Inc | Tratamiento de la invernacion del miocardio y cardiopatia diabetica con un peptido glp-1. |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
US7192922B2 (en) * | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
AU2007221366B2 (en) | 2006-02-22 | 2012-08-23 | Msd Italia S.R.L. | Oxyntomodulin derivatives |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
KR20090119876A (ko) * | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-항진물질 |
US7994122B2 (en) | 2007-06-15 | 2011-08-09 | Zealand Pharma A/S | Glucagon analogues |
CN103641907A (zh) * | 2008-06-17 | 2014-03-19 | 印第安纳大学研究及科技有限公司 | 胰高血糖素/glp-1受体共激动剂 |
CA2727161A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
WO2010107487A2 (en) * | 2009-03-18 | 2010-09-23 | Wu Nian | Lipid-drug conjugates for drug delivery |
TWI608013B (zh) * | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
-
2011
- 2011-01-20 MX MX2012008440A patent/MX342409B/es active IP Right Grant
- 2011-01-20 EA EA201290540A patent/EA026384B1/ru not_active IP Right Cessation
- 2011-01-20 BR BR112012018104A patent/BR112012018104A2/pt not_active Application Discontinuation
- 2011-01-20 EP EP11704174.9A patent/EP2525809B1/en active Active
- 2011-01-20 JP JP2012549249A patent/JP2013517307A/ja not_active Withdrawn
- 2011-01-20 NZ NZ601167A patent/NZ601167A/en not_active IP Right Cessation
- 2011-01-20 AU AU2011206979A patent/AU2011206979B2/en not_active Ceased
- 2011-01-20 CN CN201180012769XA patent/CN102892425A/zh active Pending
- 2011-01-20 US US13/574,197 patent/US20130157953A1/en not_active Abandoned
- 2011-01-20 WO PCT/DK2011/050018 patent/WO2011088837A1/en active Application Filing
- 2011-01-20 KR KR1020127021148A patent/KR20120128129A/ko active IP Right Grant
- 2011-01-20 CA CA2786934A patent/CA2786934A1/en not_active Abandoned
-
2012
- 2012-07-11 IL IL220876A patent/IL220876A0/en unknown
- 2012-07-20 CL CL2012002037A patent/CL2012002037A1/es unknown
-
2016
- 2016-04-01 JP JP2016074097A patent/JP6200025B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016138127A (ja) | 2016-08-04 |
EA026384B1 (ru) | 2017-04-28 |
MX2012008440A (es) | 2012-08-15 |
EP2525809A1 (en) | 2012-11-28 |
CA2786934A1 (en) | 2011-07-28 |
IL220876A0 (en) | 2012-09-24 |
KR20120128129A (ko) | 2012-11-26 |
EP2525809B1 (en) | 2016-08-03 |
JP2013517307A (ja) | 2013-05-16 |
CL2012002037A1 (es) | 2012-09-07 |
JP6200025B2 (ja) | 2017-09-20 |
EA201290540A1 (ru) | 2013-03-29 |
BR112012018104A2 (pt) | 2017-10-17 |
WO2011088837A1 (en) | 2011-07-28 |
AU2011206979B2 (en) | 2015-09-10 |
US20130157953A1 (en) | 2013-06-20 |
CN102892425A (zh) | 2013-01-23 |
AU2011206979A1 (en) | 2012-08-02 |
NZ601167A (en) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX342409B (es) | Tratamiento de enfermedades cardiacas. | |
EP2768304A4 (en) | CARDIAC STIMULATOR WITHOUT DIRECTED COMMUNICATION PROBE | |
MX2016005556A (es) | Compuestos agonistas duales de gip-glp-1 y procedimientos. | |
EA201391033A1 (ru) | Ингибиторы bace-2 для лечения метаболических расстройств | |
WO2012104007A3 (de) | 7-azaindolderivate | |
GB201116010D0 (en) | Use of alginate oligomers to enhance the effects of antifungal agents | |
PH12014502286B1 (en) | Improving resistance to skeletal muscle fatigue | |
MY188227A (en) | Settable compositions comprising wollastonite and pumice and methods of use | |
MX2013002390A (es) | Tratamiento de infarto de miocardio usando antagonistas de tgf-beta. | |
MX342947B (es) | Tratamiento de diabetes tipo 2. | |
MX349254B (es) | Compuestos para el tratamiento del sindrome metabolico. | |
HK1197194A1 (en) | Left ventricular diastolic function improving agent | |
PL2531189T3 (pl) | Kompozycja kombinacyjna zawierająca jako składniki czynne L-karnitynę lub propionylo-L-karnitynę do zapobiegania lub leczenia przewlekłej niewydolności żylnej | |
PL2665793T3 (pl) | Kompozycje azeotropopodobne trans-1,1,1,4,4,4-heksafluoro-2-butenu i wody | |
PT2770979E (pt) | Composição de reticulação melhorada administrada por iontoforese, útil para o tratamento do queratocone | |
MX2018000657A (es) | Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite. | |
BR112012002353A2 (pt) | uso de inibidores nkg2d para tratamento de doenças cardiovasculares e metabólicas, tal como diabetes do tipo 2 | |
MX362111B (es) | Un metodo para mejorar la funcion hepatica. | |
EA201491455A1 (ru) | ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
PL2460509T3 (pl) | Kompozycja do leczenia brodawek | |
RS55092B1 (sr) | Upotreba 3-karboksi-n-etil-n,n-dimetilpropan-1-aminijum soli u lečenju kardiovaskularne bolesti | |
HK1197037A1 (en) | Composition to be applied to the skin, and use thereof | |
WO2011146560A3 (en) | Use of jasmonates for treating heart failure and related cardiac disorders | |
UA60249U (ru) | Способ лечения острого инфаркта миокарда | |
UA96059C2 (ru) | Применение липина как средства фригопротекторного действия |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |